| Literature DB >> 24742971 |
Elise Verron1, Heidy Schmid-Antomarchi2, Hugues Pascal-Mousselard3, Annie Schmid-Alliana2, Jean-Claude Scimeca2, Jean-Michel Bouler4.
Abstract
The recent progress in oncologic management of patients with localized cancer or metastatic disease has permitted a significant improvement in life expectancy. Nevertheless, bone metastases and their consequent skeletal-related events (SREs) are still associated with unfavorable prognosis and greatly affect quality of life. Global management of these bone metastases includes traditional local approaches (surgery, radiotherapy, etc.) and systemic administration of chemotherapeutic agents. This review focuses on treatments specific for bone metastases and, in particular, on inhibitors of bone resorption that are effective for preventing and delaying the development of SREs.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24742971 DOI: 10.1016/j.drudis.2014.04.004
Source DB: PubMed Journal: Drug Discov Today ISSN: 1359-6446 Impact factor: 7.851